BMRN Stock Recent News

BMRN LATEST HEADLINES

BMRN Stock News Image - zacks.com

Get a deeper insight into the potential performance of BioMarin (BMRN) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

zacks.com 2025 Feb 13
BMRN Stock News Image - zacks.com

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?

zacks.com 2025 Feb 12
BMRN Stock News Image - zacks.com

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com 2025 Feb 12
BMRN Stock News Image - zacks.com

BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

zacks.com 2025 Feb 05
BMRN Stock News Image - prnewswire.com

SAN RAFAEL, Calif. , Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025, at 4:30 p.m.

prnewswire.com 2025 Feb 05
BMRN Stock News Image - zacks.com

BMRN, CAKE, LDOS & ENSG's impressive interest coverage ratios highlight that these companies can withstand financial hardships.

zacks.com 2025 Feb 04
BMRN Stock News Image - zacks.com

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents investors with the better value opportunity right now?

zacks.com 2025 Jan 27
BMRN Stock News Image - zacks.com

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com 2025 Jan 27
BMRN Stock News Image - seekingalpha.com

BioMarin's stock has dropped over 26% since July 2024, raising questions about whether it's a bargain or a falling knife. Key issues include valuation, stock volatility, an underwhelming investor's day, and competition with their drug VOXZOGO. The sharp decline in share price invites a reassessment of BioMarin's current investment prospects.

seekingalpha.com 2025 Jan 23
BMRN Stock News Image - zacks.com

BMRN, AMZN, LDOS & ENSG's impressive interest coverage ratios highlight that these companies can withstand financial hardships.

zacks.com 2025 Jan 22
10 of 50